JP2012529891A5 - - Google Patents

Download PDF

Info

Publication number
JP2012529891A5
JP2012529891A5 JP2012515229A JP2012515229A JP2012529891A5 JP 2012529891 A5 JP2012529891 A5 JP 2012529891A5 JP 2012515229 A JP2012515229 A JP 2012515229A JP 2012515229 A JP2012515229 A JP 2012515229A JP 2012529891 A5 JP2012529891 A5 JP 2012529891A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
chimeric polypeptide
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012515229A
Other languages
English (en)
Japanese (ja)
Other versions
JP6166041B2 (ja
JP2012529891A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/038703 external-priority patent/WO2010148010A1/en
Publication of JP2012529891A publication Critical patent/JP2012529891A/ja
Publication of JP2012529891A5 publication Critical patent/JP2012529891A5/ja
Application granted granted Critical
Publication of JP6166041B2 publication Critical patent/JP6166041B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012515229A 2009-06-15 2010-06-15 ミオチューブラリン１（ｍｔｍ１）ポリペプチドを含むキメラポリペプチドを使用して筋細管ミオパシーを処置するための方法および組成物 Expired - Fee Related JP6166041B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26873209P 2009-06-15 2009-06-15
US61/268,732 2009-06-15
PCT/US2010/038703 WO2010148010A1 (en) 2009-06-15 2010-06-15 Methods and compositions for treatment of myotubular myopathy using chimeric polypeptides comprising myotubularih 1 (mtm1) polypeptides

Publications (3)

Publication Number Publication Date
JP2012529891A JP2012529891A (ja) 2012-11-29
JP2012529891A5 true JP2012529891A5 (enExample) 2013-08-01
JP6166041B2 JP6166041B2 (ja) 2017-07-19

Family

ID=43356726

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012515229A Expired - Fee Related JP6166041B2 (ja) 2009-06-15 2010-06-15 ミオチューブラリン１（ｍｔｍ１）ポリペプチドを含むキメラポリペプチドを使用して筋細管ミオパシーを処置するための方法および組成物

Country Status (8)

Country Link
US (2) US8834866B2 (enExample)
EP (1) EP2443155B1 (enExample)
JP (1) JP6166041B2 (enExample)
AU (1) AU2010260145B2 (enExample)
BR (1) BRPI1011236A2 (enExample)
CA (1) CA2797480A1 (enExample)
ES (1) ES2630057T3 (enExample)
WO (1) WO2010148010A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010260145B2 (en) 2009-06-15 2015-08-20 Valerion Therapeutics, Llc Methods and compositions for treatment of Myotubular Myopathy using chimeric polypeptides comprising myotubularin 1 (MTM1) polypeptides
JP6178785B2 (ja) 2011-04-01 2017-08-09 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ 細胞浸透性抗ｄｎａ抗体およびｄｎａ修復を阻害するためのその使用
US9610362B2 (en) 2012-03-16 2017-04-04 Valerion Therapeutics, Llc Antisense conjugates for decreasing expression of DMPK
US9732146B2 (en) * 2012-03-30 2017-08-15 The United States Of America As Represented By The Department Of Veterans Affairs Antibody-mediated transduction of heat shock proteins into living cells
US20150152170A1 (en) * 2012-05-23 2015-06-04 Valerion Therapeutics, Llc Methods for increasing muscle contractility
JP2016514096A (ja) 2013-02-20 2016-05-19 バレリオン セラピューティクス， エルエルシー ポンぺ病の処置のための方法および組成物
US8957044B2 (en) 2013-03-01 2015-02-17 Wake Forest University Health Sciences Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM)
FR3004463A1 (fr) 2013-04-11 2014-10-17 Genethon Systeme d'expression pour une therapie genique selective
WO2015106290A1 (en) 2014-01-13 2015-07-16 Valerion Therapeutics, Llc Internalizing moieties
WO2015128846A1 (en) * 2014-02-28 2015-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Broadly neutralizing monoclonal antibodies against hiv-1 v1v2 env region
EP3154570A4 (en) 2014-06-13 2017-12-27 Valerion Therapeutics, LLC Methods and compositions for treatment of glycogen storage diseases and glycogen metabolism disorders
CA2995673A1 (en) 2014-08-27 2016-03-03 Valerion Therapeutics, Llc Internalizing moieties for treatment of cancer
US10383945B2 (en) 2015-02-18 2019-08-20 The United States of America as Represented by the Department of Verterans Affairs Methods for DNA-dependent targeting of a cell permeant antibody
US12486318B2 (en) 2016-06-15 2025-12-02 Yale University Anti-guanosine antibody as a molecular delivery vehicle
EP3471777A1 (en) 2016-06-15 2019-04-24 Yale University Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors
CA3036524A1 (en) * 2016-09-09 2018-03-15 Valerion Therapeutics, Llc Methods and compositions for treatment of lafora disease
JP2020529836A (ja) * 2017-07-03 2020-10-15 ユニヴェルシテ・ドゥ・ストラスブール ミオパチーの処置における使用のためのｍｔｍｒ２−ｓポリペプチド
KR20220101073A (ko) * 2019-08-30 2022-07-19 예일 유니버시티 핵산을 세포로 전달하기 위한 조성물 및 방법
KR20230154921A (ko) * 2021-03-03 2023-11-09 예일 유니버시티 골격근 질환을 치료하기 위한 조성물 및 방법
GB202201713D0 (en) * 2022-02-10 2022-03-30 Univ Dundee An affinity directed phosphatase system for targeted protein dephosphorylation
AU2024271851A1 (en) 2023-05-16 2025-12-18 Affinia Therapeutics Inc. Recombinant aavs with improved tropism and specificity

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US6068829A (en) 1995-09-11 2000-05-30 The Burnham Institute Method of identifying molecules that home to a selected organ in vivo
US5622699A (en) 1995-09-11 1997-04-22 La Jolla Cancer Research Foundation Method of identifying molecules that home to a selected organ in vivo
WO1997032602A1 (en) 1996-03-08 1997-09-12 The Regents Of The University Of California DELIVERY SYSTEM USING mAb 3E10 AND MUTANTS AND/OR FUNCTIONAL FRAGMENTS THEREOF
US6329501B1 (en) 1997-05-29 2001-12-11 Auburn University Methods and compositions for targeting compounds to muscle
US6180084B1 (en) 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
JPH11151088A (ja) 1997-11-20 1999-06-08 Univ Tokyo 脱リン酸化反応を触媒する新規酵素
US6232287B1 (en) 1998-03-13 2001-05-15 The Burnham Institute Molecules that home to various selected organs or tissues
US6174687B1 (en) 1999-02-26 2001-01-16 The Burnham Institute Methods of identifying lung homing molecules using membrane dipeptidase
US6303573B1 (en) 1999-06-07 2001-10-16 The Burnham Institute Heart homing peptides and methods of using same
US6551809B2 (en) 2001-03-20 2003-04-22 Applera Corporation Isolated human phosphatase proteins, nucleic acid molecules encoding human phophatase proteins, and uses thereof
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
EP1755648A2 (en) * 2004-05-27 2007-02-28 Acceleron Pharma Inc. Cerberus/coco derivatives and uses thereof
AU2008207948A1 (en) * 2007-01-22 2008-07-31 The United States Government As Represented By The Department Of Veterans Affairs Use of antibody conjugates
JP2010527618A (ja) 2007-05-24 2010-08-19 アメリカ合衆国 ヌクレオシドサルベージ経路を通しての核内タンパク質伝達
CA2777486A1 (en) 2008-10-15 2010-04-22 4S3 Bioscience Inc. Methods and compositions for treatment of myotonic dystrophy
US9155801B2 (en) 2009-05-28 2015-10-13 The United States Government As Represented By The Department Of Veterans Affairs Amino acid sequences which enhance peptide conjugate solubility
AU2010260145B2 (en) 2009-06-15 2015-08-20 Valerion Therapeutics, Llc Methods and compositions for treatment of Myotubular Myopathy using chimeric polypeptides comprising myotubularin 1 (MTM1) polypeptides
GB2476671B (en) 2010-01-04 2014-11-26 Plastic Logic Ltd Touch-sensing systems
JP5240316B2 (ja) 2010-10-26 2013-07-17 株式会社デンソー 車両乗員非操作運転システム
KR20140035357A (ko) 2011-04-05 2014-03-21 셰브런 오로나이트 컴퍼니 엘엘씨 저점도 선박 실린더 윤활유 조성물
US20150152170A1 (en) 2012-05-23 2015-06-04 Valerion Therapeutics, Llc Methods for increasing muscle contractility

Similar Documents

Publication Publication Date Title
US11833120B2 (en) Binding protein drug conjugates comprising anthracycline derivatives
CN107849148B (zh) 三特异性结合蛋白质及使用方法
JP4011914B2 (ja) キメラポリペプチド、その製造方法、およびその使用
AU2018362349B2 (en) Improved TfR-selective binding peptides capable of crossing the blood brain barrier
US20180106790A1 (en) Single chain proteins with c-terminal modifications
CN106661128A (zh) 构建氨基末端免疫球蛋白融合蛋白的方法及其组合物
US20240279360A1 (en) Bifunctional compounds containing igf-2 polypeptides
US9474794B2 (en) Antibodies that bind to adrenomedullin and to adrenomedullin receptors and the uses thereof as drugs
JP2023145635A (ja) 免疫調節特性を有するペプチド
JP2020072685A (ja) クロストリジウム・ディフィシル感染症の治療のための、クロストリジウム・ディフィシルのトキシンａ及びトキシンｂに対する四重特異性の八量体型結合剤及び抗体
CN107206103A (zh) 用于治疗目的的抗体‑脲酶缀合物
US20180028682A1 (en) Maytansine-drug conjugates of her-2 specific binding proteins generated by site specific sortase-enzyme mediated conjugation
JP2019535645A5 (enExample)
JP2016027801A (ja) 改良された抗血清アルブミン結合変異体
US20210401927A1 (en) Peptides Having Immunomodulatory Properties
US10072065B2 (en) Peptide-mediated delivery of immunoglobulins across the blood-brain barrier
US20220143130A1 (en) Peptides Having Immunomodulatory Properties
US11952402B2 (en) Fusion protein containing trail and IgG binding domain and the uses thereof
CN117510642A (zh) 一种全基因编码的双靶向嵌合体及其应用
US11952410B2 (en) Mesothelin-targeted trail trimer
Xu et al. Fusion of parathyroid hormone (1–34) to an albumin-binding domain improves osteogenesis
CN109641066B (zh) 新的IgG结合肽和含有该肽的多功能抗原结合蛋白
WO2022240407A1 (en) Delivery constructs derived from bacterial toxins and uses thereof
NZ794344A (en) Tgfβr2 extracellular domain truncated molecule, fusion protein of tgfβr2 extracellular domain truncated molecule and anti-egfr antibody, and anti-tumor use of fusion protein